Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 18 July 2017

Enzymatica recruits Chief Commercial Officer

Enzymatica AB    

Published: 08:30 CEST 18-07-2017 /GlobeNewswire /Source: Enzymatica AB / : ENZY /ISIN: SE0003943620

Enzymatica recruits Chief Commercial Officer

Press release

Lund, 18 July 2017


Enzymatica recruits Chief Commercial Officer


Enzymatica has recruited Claus Egstrand as its Chief Commercial Officer. Claus Egstrand's primary responsibility will be to develop Enzymatica's international business, focusing on distributor agreements and also, in the longer term, on the launch of new products. Claus has many years of experience from pharmaceutical and medical technology companies such as Merck & Co, Pfizer, Stryker Corporation, Pharmacia and Johnson&Johnson/Merck Pharmaceuticals.


"There are great growth opportunities for Enzymatica with its patented barrier technology on which the common cold spray ColdZyme® is based.  I look forward to being able to contribute with my experience in building successful brands and international pharmaceutical and medical technology companies. My aim is to contribute towards Enzymatica becoming a first-class self-care company in the global market."


"We are delighted to have recruited Claus who, with his experience and contacts in the life science industry, will be key to our international expansion, particularly in contact and negotiations with international partners," says Fredrik Lindberg, CEO of Enzymatica, continuing:


"Claus has an impressive background, having repeatedly demonstrated his ability to lead the build-up of businesses with two-digit growth rates, in terms of both sales and profits."


Claus Egstrand's previous positions have included being Head of Europe for MSD Consumer Care in the pharmaceutical company Merck & Co, Vice President, General Manager Medsurg Europe in the medical device company Stryker Corporation, Senior Vice President Consumer Healthcare for Latin America, Africa, Asia, Japan and Australia in the pharmaceutical company Pfizer, Vice President and head of global marketing for the smoking cessation product Nicorette in the pharmaceutical company Pharmacia and CEO of the Johnson&Johnson/Merck Pharmaceuticals' operation in France. He joins Enzymatica from a position as Group President, International at HOLOGIC CORP.


For more information, contact:

Fredrik Lindberg, CEO of Enzymatica AB
Tel: +46 (0)708-86 53 70, e-mail  fredrik.lindberg@enzymatica.com   


About Enzymatica AB

Enzymatica AB is a medical device company that develops and sells medical devices for infection-related diseases. In a short period of time, the company has developed ColdZyme®, a unique mouth spray for the common cold, has launched the product in eight markets and has established it among the top-selling cold products in Swedish kronor terms at Swedish pharmacies. The strategy is to continue to grow by strengthening the company's position in existing markets and expanding into new geographical markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.se

Enzymatica's Certified Adviser is Erik Penser Bank.


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Enzymatica AB, Ideon Science Park, Lund SE-223 70, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.